Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid CancerAdvanced Solid Tumor (Phase 1)
- Interventions
- Drug: APX-343A
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT07123415
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT06962098
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan-si, Korea, Republic of
🇰🇷Inje university Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
- Conditions
- Contrast Induced Acute Kidney Injury
- Interventions
- Drug: PlaceboDrug: Isuzinaxib (APX-115)
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT05758896
- Locations
- 🇺🇸
Florida Cardiovascular Research, Hialeah, Florida, United States
🇺🇸Sarkis Clinical Trials, Ocala, Florida, United States
🇰🇷Kangwon National University Hospital, Chuncheon, Korea, Republic of
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04880109
- Locations
- 🇺🇸
Alternative Research Associates, LLC, Hialeah, Florida, United States
🇺🇸Anne Arundel Medical Center, Baltimore, Maryland, United States
🇺🇸Millennium Physicians Group, Houston, Texas, United States
Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
- Conditions
- Nephropathy, DiabeticDiabetic NephropathiesDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04534439
- Locations
- 🇧🇬
Pleven, Pleven, Bulgaria
🇧🇬Sveta Karidad, Plovdiv, Bulgaria
🇧🇬Diagnostic-consultative centre I, Sliven, Bulgaria
- Prev
- 1
- 2
- Next